December 3, 2007 - Treating throat cancer with intensity modulated radiation therapy (IMRT) can improve the health-related quality of life of patients compared to conventional radiation therapy (CRT), according to a study in the December issue of the International Journal for Radiation Oncology*Biology*Physics, the official journal of the American Society for Therapeutic Radiology and Oncology.

Oropharyngeal cancer, sometimes referred to as throat cancer, is a cancer that develops in the part of the throat located just behind the mouth, called the oropharynx. This includes cancer in the tonsil and in the back of the tongue. Squamous cell carcinomas, originating from the cells that normally form the lining of the mouth and throat, account for more than 90 percent of oropharyngeal cancers. In recent years, there is a trend for younger people and nonsmokers to develop this cancer.

The focus of the study, conducted by the University of Iowa Department of Radiation Oncology and Department of Otolaryngology – Head and Neck Surgery, was to compare the health-related quality of life outcomes of patients diagnosed with oropharyngeal cancer treated with IMRT versus CRT.

“It is important for patients to be able to preserve the quality of life they had before they were diagnosed and began treatment for cancer,” said Min Yao, M.D., Ph.D., lead author of the study and an associate professor at the University of Texas Southwestern Medical School Department of Radiation Oncology. “This study will be invaluable for patients diagnosed with oropharyngeal squamous cell carcinoma who are weighing treatment options because now they know that IMRT can offer them with better quality of life.”

CRT aims two or three external radiation beams at the tumor. Large amount of adjacent normal organs, including the oral cavity and salivary glands, receive radiation doses as high as the tumor. The salivary glands are totally destroyed by the radiation and some patients suffer from severe mouth dryness with poor quality of life.

IMRT is a new technology that is different from CRT. It uses multiple radiation beams that are broken up into many smaller beamlets. This allows radiation oncologists to precisely target the radiation to the tumor and spare the adjacent normal structures from high doses of radiation. The functions of these structures, especially the salivary glands, are preserved.

The study involved 53 patients from the database of the Outcomes Assessment Project funded by National Institutes of Health. This is an ongoing longitudinal study initiated more than 10 years ago to prospectively collect outcome data from individuals diagnosed with carcinomas of the upper aerodigestive tract. Twenty-six of the study’s patients were treated with IMRT, and 27 were treated using CRT.

The data used in the study were collected before treatment began and at 3, 6 and 12 months after treatment ended. Participants were also required to complete quality of life surveys, which scored patients’ eating, speech, aesthetics (e.g. changes in their physical appearance), and social disruption (e.g. changes in how they interact with others) during the various time points.

The study found that at 12 months after treatment ended, the patients treated with IMRT had better health-related quality of life in all four scored areas; however, the greatest difference in quality of life between the two treatment groups was seen in eating. Patients treated with IMRT were found to have improvement in their eating six months after treatment and continued to improve during the first 12 months after treatment. Patients who received CRT continued to deteriorate after six months with minimal improvement after 12 months.

For more information: www.astro.org


Related Content

News | Radiation Oncology

July 9, 2024 — Insights from the latest Mordor Intelligence report, “Radiotherapy Market Size & Share Analysis - Growth ...

Time July 09, 2024
arrow
News | Artificial Intelligence

September 7, 2023 — Paige, a provider of end-to-end digital pathology solutions and clinical AI, has announced a ...

Time September 07, 2023
arrow
News | Radiology Business

July 27, 2023 — Privately-held biotech company TAE Life Sciences has announced that its board of directors has appointed ...

Time July 27, 2023
arrow
News | Intensity Modulated Radiation Therapy (IMRT)

March 14, 2022 — RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy ...

Time March 14, 2022
arrow
News | Intensity Modulated Radiation Therapy (IMRT)

October 22, 2021 — RefleXion Medical, a therapeutic oncology company pioneering biology-guided radiotherapy* (BgRT) as a ...

Time October 22, 2021
arrow
News | Intensity Modulated Radiation Therapy (IMRT)

October 27, 2020 — A preliminary analysis of photon therapy treatment group 1 from the phase II NRG Oncology clinical ...

Time October 27, 2020
arrow
News | Radiation Therapy

June 10, 2020 — A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides ...

Time June 10, 2020
arrow
News | Radiation Therapy

April 16, 2020 — RefleXion Medical, a therapeutic oncology company pioneering the use of biology-guided radiotherapy ...

Time April 16, 2020
arrow
News | Proton Therapy

January 29, 2020 — IBA (Ion Beam Applications S.A.) announced that it has signed a contract and received a major down ...

Time January 29, 2020
arrow
News | Interventional Radiology

Varian announced it has signed an asset purchase agreement to acquire the Boston Scientific portfolio of drug-loadable microsphere and bland embolic bead products for treating arteriovenous malformations and hypervascular tumors. When completed, this acquisition, in combination with the recent acquisitions of Endocare and Alicon, will expand Varian's portfolio of multidisciplinary integrated cancer care solutions.

Time July 03, 2019
arrow
Subscribe Now